| Therapeutic | Inotuzumab |
| Target | CD22 |
| Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS |
| Light Chain | DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb ADC |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2004 |
| INN Year Recommended | 2005 |
| Companies Involved | Alliance for Clinical Trials in Oncology, Cancer Research UK, Case Comprehensive Cancer Center, Children's Oncology Group, Erasmus MC, M. D. Anderson Cancer Center, National Cancer Institute (USA), Pfizer, SWOG, University College London, University of Texas M. D. Anderson Cancer Center, Celltech Group |
| Conditions Approved | Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Active | Precursor B-cell lymphoblastic leukaemia-lymphoma, Chronic myeloid leukaemia |
| Conditions Discontinued | Acute biphenotypic leukaemia, Burkitt's lymphoma, Diffuse large B cell lymphoma, Non-Hodgkin's lymphoma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
